Signal Transduction and Therapeutics

信号转导和治疗

• 批准号: 7944561
• 负责人: Fuyuhiko Tamanoi
• 金额: $ 7.8万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-02 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944561
• 关键词: Agonist; Antineoplastic Agents; Area; Basic Science; Biochemistry; Cancer Center Support Grant; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Comprehensive Cancer Center; Consultations; Development; Division of Basic Sciences; Drug Delivery Systems; Drug Industry; Fostering; Funding; Gifts; Gleevec; Goals; Grant; Institutes; Institution; Investigation; Joints; Jonsson Comprehensive Cancer Center of University of California Los Angeles; Journals; Laboratories; Leadership; Malignant Neoplasms; Monitor; National Cancer Institute; Normal Cell; Pathway interactions; Peer Review; Pharmaceutical Preparations; Phosphotransferases; Play; Predisposition; Process; Program Reviews; Progress Reports; Publications; Reading; Research; Research Personnel; Resource Sharing; Resources; Role; Schedule; Scientist; Screening procedure; Seeds; Series; Signal Pathway; Signal Transduction; Signal Transduction Inhibitor; Signal Transduction Pathway; Signaling Molecule; Suggestion; Therapeutic; Therapeutic Human Experimentation; Translational Research; base; clinical application; cost; design; drug development; inhibitor/antagonist; interest; meetings; member; neoplastic cell; novel; novel therapeutics; pre-clinical; programs; research study; response; small molecule; translational study; tumor

The Signal Transduction and Therapeutics Program Area is composed of 37 members, spanning 16 Departments within UCLA. In the past competing cycle, investigators from this Program authored 374 publications, of which 150 (40%) were inter-programmatic and 86 (23%) intra-programmatic. 143 (38%) were placed in high-impact journals. 27 members of this Program Area used 8 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled ~$16 million in total costs, including $3.6 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the STT Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the STT Program Area total $2,987,635. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twenty-four of the Program Area Members were the recipients of JCCC support. Since its inception in 1996, the Signal Transduction Program Area has been engaged in investigating both basic mechanisms of signal transduction in normal cells and alterations in signal transduction in tumor cells. During the current CCSG funding period, we have seen increased activity in translational research, with the long-term aim of bringing basic science findings to clinical application. A number of activities, including joint meetings with clinical Program Areas, culminated in the merger of the Signal Transduction Program Area with a portion of the membership of .Cancer Translational Therapeutics Program Area. This extended and enriched Program Area is now called the Signal Transduction and Therapeutics Program Area. These changes were also made in response to the 2002 CCSG review suggestions to place greater emphasis on translational research, and after extensive consultation with our External Advisory Board. The goals of our new Program Area are: (1) to characterize signaling pathways and identify novel signaling molecules; (2) to understand differences in signaling between cancer and normal cells; (3) to promote clinical trials with signaling inhibitors; and (4) to promote close cooperation between basic and clinical science. To facilitate these goals, we have instituted a number of Program Area activities. Specifically, we have organized three different seminar series. We continue with the "Signal Transduction and Therapeutics Research" seminars as well as seminars by outside speakers. In addition, we have a regularly scheduled "Signal Transduction and Therapeutics Program Area Lunch" for our members. Finally, we have initiated a new type of meeting: a "Signal Transduction and Therapeutics Round Table Discussion" to bring together basic scientists and clinicians.

信号转导和治疗计划区由37名成员组成，跨越16个国家和地区。 加州大学洛杉矶分校内的部门。在过去的竞争周期中，来自该计划的调查人员撰写了374份 这些出版物中有150份（40%）是方案间出版物，86份（23%）是方案内出版物。143人（38%） 发表在高影响力期刊上。该计划领域的27名成员使用了8个共享资源中的8个， 目前由JCCC资助。在本资助年度，同行评审的资金总额约为1600万美元 总成本，包括来自国家癌症研究所的360万美元。与其他计划领域一样，JCCC 促进了一些互动活动和许多共享资源，支持调查人员在 STT程序区。在目前的赠款周期内，来自JCCC的资金以CCSG发展的形式提供， 向短期培训方案领域提供的资金、机构支助和慈善捐赠总额为2 987 635美元。这些资金 支持跨学科赠款、种子赠款、招聘/保留、计划领域领导支持， 为新出现的共享资源和受训人员的使用提供资金。24个项目区成员 是JCCC支持的受益者。 自1996年成立以来，信号转导计划领域一直致力于研究 正常细胞中信号转导的基本机制和肿瘤细胞中信号转导的改变。 在当前的CCSG资助期间，我们看到转化研究的活动有所增加， 长期目标是将基础科学成果应用于临床。一些活动，包括联合 会议与临床程序区，最终在合并的信号转导程序区与 癌症转化治疗计划领域的一部分成员。这扩展和丰富了 该计划领域现在被称为信号转导和治疗计划领域。这些变化 2002年CCSG审查建议更加重视翻译， 研究，并与我们的外部咨询委员会进行了广泛的咨询。我们新计划的目标 主要研究领域是：（1）表征信号通路和识别新的信号分子;（2）了解 癌细胞和正常细胞之间的信号差异;（3）促进信号抑制剂的临床试验; （4）促进基础科学与临床科学的密切合作。为了实现这些目标，我们 开展了多项方案领域活动。具体而言，我们举办了三个不同的研讨会系列。 我们继续举办“信号传导和治疗研究”研讨会以及 外扬声器此外，我们还有一个定期安排的“信号转导和治疗方案 “午餐”是为我们的会员准备的。最后，我们发起了一种新型的会议：“信号转导和 治疗圆桌讨论”，汇集了基础科学家和临床医生。